{"id": "article-22666_0", "title": "Heart Transplantation Rejection -- Continuing Education Activity", "content": "Heart transplantation (HTx) is a procedure performed in patients with end-stage heart failure (HF) who remain symptomatic despite appropriate medical therapy. Heart transplant rejection occurs when the recipient's immune system reacts to the foreign antigens in the donor organ by mounting an immune response. Patients will present with signs and symptoms of heart failure, such as shortness of breath, orthopnea, paroxysmal nocturnal dyspnea, palpitations, syncope, etc. This activity illustrates the evaluation and management of heart transplantation rejection and explains the role of the interprofessional team in improving care for patients with this condition.", "contents": "Heart Transplantation Rejection -- Continuing Education Activity. Heart transplantation (HTx) is a procedure performed in patients with end-stage heart failure (HF) who remain symptomatic despite appropriate medical therapy. Heart transplant rejection occurs when the recipient's immune system reacts to the foreign antigens in the donor organ by mounting an immune response. Patients will present with signs and symptoms of heart failure, such as shortness of breath, orthopnea, paroxysmal nocturnal dyspnea, palpitations, syncope, etc. This activity illustrates the evaluation and management of heart transplantation rejection and explains the role of the interprofessional team in improving care for patients with this condition."}
{"id": "article-22666_1", "title": "Heart Transplantation Rejection -- Continuing Education Activity", "content": "Objectives: Evaluate\u00a0the pathophysiology of heart transplantation rejection. Evaluate\u00a0the ISHLT ACR grading of heart transplantation rejection. Assess the evaluation of heart transplantation rejection. Explain the importance of improving care coordination among the interprofessional team to enhance care delivery for patients with heart transplantation rejection. Access free multiple choice questions on this topic.", "contents": "Heart Transplantation Rejection -- Continuing Education Activity. Objectives: Evaluate\u00a0the pathophysiology of heart transplantation rejection. Evaluate\u00a0the ISHLT ACR grading of heart transplantation rejection. Assess the evaluation of heart transplantation rejection. Explain the importance of improving care coordination among the interprofessional team to enhance care delivery for patients with heart transplantation rejection. Access free multiple choice questions on this topic."}
{"id": "article-22666_2", "title": "Heart Transplantation Rejection -- Introduction", "content": "Heart transplantation (HTx) is a procedure limited to patients with end-stage heart failure who remain symptomatic despite being on optimal medical and device therapy. Guidelines identifying potential HTx candidates were updated in 2016 by the International Society for Heart and Lung Transplantation (ISHLT). Stringent selection criteria and immunosuppressive therapy post-transplantation have led to improved prognosis. Despite the progress and improved overall outcomes, heart transplantation rejection (HTR) remains the Achilles heel of transplantation. The manifestation of rejection can occur as early as intraoperatively to\u00a0many years after transplant. The timing of HTR plays a significant role in establishing cause and diagnosis. Based on timings, HTR can either be due to early graft dysfunction within the first 24 hours or late graft dysfunction, developing weeks to years after transplantation.", "contents": "Heart Transplantation Rejection -- Introduction. Heart transplantation (HTx) is a procedure limited to patients with end-stage heart failure who remain symptomatic despite being on optimal medical and device therapy. Guidelines identifying potential HTx candidates were updated in 2016 by the International Society for Heart and Lung Transplantation (ISHLT). Stringent selection criteria and immunosuppressive therapy post-transplantation have led to improved prognosis. Despite the progress and improved overall outcomes, heart transplantation rejection (HTR) remains the Achilles heel of transplantation. The manifestation of rejection can occur as early as intraoperatively to\u00a0many years after transplant. The timing of HTR plays a significant role in establishing cause and diagnosis. Based on timings, HTR can either be due to early graft dysfunction within the first 24 hours or late graft dysfunction, developing weeks to years after transplantation."}
{"id": "article-22666_3", "title": "Heart Transplantation Rejection -- Etiology", "content": "Etiology for HTR varies based on the onset of rejection. Early graft dysfunction can be primary or secondary. Primary graft dysfunction (PGD): The universally accepted standard definition for PGD is lacking. Ventricular dysfunction causing cardiogenic shock and requiring circulatory support such as inotropes/mechanical support devices in the absence of recipient alloimmune response or other discernible causes is endorsed as PGD. Various factors implicated in the development of PGD are: Pre-existing donor heart disease Re-perfusion injury immediately post-transplant Allograft injury occurs during organ retrieval, conservation, and implantation. [1] Secondary graft dysfunction: secondary graft dysfunction results from identifiable causes such as: Hyperacute graft rejection Increased pressure or volume load on the right ventricle Undiagnosed recipient pulmonary hypertension", "contents": "Heart Transplantation Rejection -- Etiology. Etiology for HTR varies based on the onset of rejection. Early graft dysfunction can be primary or secondary. Primary graft dysfunction (PGD): The universally accepted standard definition for PGD is lacking. Ventricular dysfunction causing cardiogenic shock and requiring circulatory support such as inotropes/mechanical support devices in the absence of recipient alloimmune response or other discernible causes is endorsed as PGD. Various factors implicated in the development of PGD are: Pre-existing donor heart disease Re-perfusion injury immediately post-transplant Allograft injury occurs during organ retrieval, conservation, and implantation. [1] Secondary graft dysfunction: secondary graft dysfunction results from identifiable causes such as: Hyperacute graft rejection Increased pressure or volume load on the right ventricle Undiagnosed recipient pulmonary hypertension"}
{"id": "article-22666_4", "title": "Heart Transplantation Rejection -- Etiology", "content": "Acute allograft rejection can be cellular or antibody (humoral) mediated. Risk factors include younger patients, female donors or recipients, and increased HLA mismatches. [2] Cardiac allograft vasculopathy (CAV). Risk factors include elevated cholesterol levels, cytomegalovirus infection, insulin resistance, coronary heart disease in the donor and younger recipient, and a history of acute rejection. Other causes of allograft failure include recurrence of myocardial conditions such as amyloidosis, sarcoidosis, giant cell myocarditis, hereditary hemochromatosis, and malignancy such as primary cardiac lymphoma.", "contents": "Heart Transplantation Rejection -- Etiology. Acute allograft rejection can be cellular or antibody (humoral) mediated. Risk factors include younger patients, female donors or recipients, and increased HLA mismatches. [2] Cardiac allograft vasculopathy (CAV). Risk factors include elevated cholesterol levels, cytomegalovirus infection, insulin resistance, coronary heart disease in the donor and younger recipient, and a history of acute rejection. Other causes of allograft failure include recurrence of myocardial conditions such as amyloidosis, sarcoidosis, giant cell myocarditis, hereditary hemochromatosis, and malignancy such as primary cardiac lymphoma."}
{"id": "article-22666_5", "title": "Heart Transplantation Rejection -- Epidemiology", "content": "According to ISHLT, 5,074 heart transplants were performed in 2015. Median survival for cardiac transplants performed between 1982 and June 2015 was 10.7 years for adult recipients and 16.1 years for pediatric recipients. Survival rates in adults post-transplant were 94.8%, 84.1%, and 72.3% after 1, 5, and 10 years, respectively. The rates of HTR have steadily declined with the use of immunosuppressive therapy. HTR rates after discharge to 1 year of follow-up have declined from 30.5% in 2004-2006 to 24.10% in 2010-2015. [3]", "contents": "Heart Transplantation Rejection -- Epidemiology. According to ISHLT, 5,074 heart transplants were performed in 2015. Median survival for cardiac transplants performed between 1982 and June 2015 was 10.7 years for adult recipients and 16.1 years for pediatric recipients. Survival rates in adults post-transplant were 94.8%, 84.1%, and 72.3% after 1, 5, and 10 years, respectively. The rates of HTR have steadily declined with the use of immunosuppressive therapy. HTR rates after discharge to 1 year of follow-up have declined from 30.5% in 2004-2006 to 24.10% in 2010-2015. [3]"}
{"id": "article-22666_6", "title": "Heart Transplantation Rejection -- Epidemiology", "content": "The incidence of PGD varies from 20-40%. A 6-year follow-up study published in 2018 reported a PGD incidence of 31% in post-transplant patients. [4] A similar study published in 2011 disclosed a PGD incidence rate of 23%. [5] Deaths due to\u00a0acute allograft rejection reach up to 11% in the first 3 years after transplant. Nearly half of heart transplant recipients developing rejection after 7 years of transplantation have evidence of antibody-mediated rejection. The overall prevalence of CAV increases with time.\u00a0CAV is the leading cause of death between 1 and 3 years after transplantation. [6] CAV accounts for 17% of death after 3 years. [7]", "contents": "Heart Transplantation Rejection -- Epidemiology. The incidence of PGD varies from 20-40%. A 6-year follow-up study published in 2018 reported a PGD incidence of 31% in post-transplant patients. [4] A similar study published in 2011 disclosed a PGD incidence rate of 23%. [5] Deaths due to\u00a0acute allograft rejection reach up to 11% in the first 3 years after transplant. Nearly half of heart transplant recipients developing rejection after 7 years of transplantation have evidence of antibody-mediated rejection. The overall prevalence of CAV increases with time.\u00a0CAV is the leading cause of death between 1 and 3 years after transplantation. [6] CAV accounts for 17% of death after 3 years. [7]"}
{"id": "article-22666_7", "title": "Heart Transplantation Rejection -- Pathophysiology -- Primary Graft Dysfunction", "content": "The \u201cischemic time,\u201d defined from cross-clamping the donor heart to implantation in the recipient patient, subjects the donor heart to various forms of insult. The effect of ischemic time on PGD depends on donor age [8] . The donor body experiences catecholamine stress during the time of brain death. This catecholamine surge increases oxygen demand, subsequently causing myocardial ischemia and desensitization of the myocardial beta-receptor transduction system, activating multiple proinflammatory mediators. Hypothermic storage before implantation slows down the metabolic activity of allograft. Prolonged storage can lead to loss of normal aerobic metabolism resulting in an anaerobic switch and causing lactic acidosis. Further, allograft reperfusion enhances calcium overload at the time of implantation, contributing to myocardial stunning. Secondary graft dysfunction resulting from hyperacute rejection is either\u00a0due to ABO incompatibility or from pre-formed cytotoxic antibodies that direct their activities against significant histocompatibility (MHC) antigens on the allograft.", "contents": "Heart Transplantation Rejection -- Pathophysiology -- Primary Graft Dysfunction. The \u201cischemic time,\u201d defined from cross-clamping the donor heart to implantation in the recipient patient, subjects the donor heart to various forms of insult. The effect of ischemic time on PGD depends on donor age [8] . The donor body experiences catecholamine stress during the time of brain death. This catecholamine surge increases oxygen demand, subsequently causing myocardial ischemia and desensitization of the myocardial beta-receptor transduction system, activating multiple proinflammatory mediators. Hypothermic storage before implantation slows down the metabolic activity of allograft. Prolonged storage can lead to loss of normal aerobic metabolism resulting in an anaerobic switch and causing lactic acidosis. Further, allograft reperfusion enhances calcium overload at the time of implantation, contributing to myocardial stunning. Secondary graft dysfunction resulting from hyperacute rejection is either\u00a0due to ABO incompatibility or from pre-formed cytotoxic antibodies that direct their activities against significant histocompatibility (MHC) antigens on the allograft."}
{"id": "article-22666_8", "title": "Heart Transplantation Rejection -- Pathophysiology -- Acute Allograft Rejection (Cellular versus humoral mechanism)", "content": "Acute Cellular Rejection (ACR): Major and minor histocompatibility antigens are not expressed equally among all individuals; this increases the potential of such proteins to act as alloantigens and activate alloimmunity by stimulating cytotoxic T cells. T cells respond to these donor antigens either directly or indirectly based on the method of antigen presentation. T cells can directly recognize donor MHC molecules on allograft or target when presented indirectly by recipient antigen-presenting cells (APC). [9] interleukin-2 (IL-2), tumor necrosis factor-beta (TNF-beta), and interferon-gamma (IFN-gamma) all act as significant mediators during rejection.", "contents": "Heart Transplantation Rejection -- Pathophysiology -- Acute Allograft Rejection (Cellular versus humoral mechanism). Acute Cellular Rejection (ACR): Major and minor histocompatibility antigens are not expressed equally among all individuals; this increases the potential of such proteins to act as alloantigens and activate alloimmunity by stimulating cytotoxic T cells. T cells respond to these donor antigens either directly or indirectly based on the method of antigen presentation. T cells can directly recognize donor MHC molecules on allograft or target when presented indirectly by recipient antigen-presenting cells (APC). [9] interleukin-2 (IL-2), tumor necrosis factor-beta (TNF-beta), and interferon-gamma (IFN-gamma) all act as significant mediators during rejection."}
{"id": "article-22666_9", "title": "Heart Transplantation Rejection -- Pathophysiology -- Acute Humoral/Antibody Rejection (AMR)", "content": "Antibody-mediated humoral rejection is poorly understood. The antibody reacts to donor MHC antigens (HLA-I and II), leading to capillary endothelial changes. The deposition of immunoglobulin and complements within the myocardial capillary bed are detectable by immunofluorescence. [10]", "contents": "Heart Transplantation Rejection -- Pathophysiology -- Acute Humoral/Antibody Rejection (AMR). Antibody-mediated humoral rejection is poorly understood. The antibody reacts to donor MHC antigens (HLA-I and II), leading to capillary endothelial changes. The deposition of immunoglobulin and complements within the myocardial capillary bed are detectable by immunofluorescence. [10]"}
{"id": "article-22666_10", "title": "Heart Transplantation Rejection -- Pathophysiology -- CAV", "content": "Endothelial damage in CAV can be immune or non-immune-mediated. Endothelial damage leads to mild intimal thickening before progressing to diffuse fibrous thickening of the intima. [11] More recent research has established the role of effector B-cells with CAV. [12]", "contents": "Heart Transplantation Rejection -- Pathophysiology -- CAV. Endothelial damage in CAV can be immune or non-immune-mediated. Endothelial damage leads to mild intimal thickening before progressing to diffuse fibrous thickening of the intima. [11] More recent research has established the role of effector B-cells with CAV. [12]"}
{"id": "article-22666_11", "title": "Heart Transplantation Rejection -- Histopathology", "content": "ACR is a mononuclear inflammatory response infiltrating myocardial tissue with predominant lymphocytic cells.\u00a0Immunohistologic assessment can confirm the presence of\u00a0CD-4 and CD-8 positive T lymphocytes with high affinity to interleukin-2 receptors. Increased intercellular adhesion molecules with high MHC-II expression on cardiac myocytes are present. These findings should be distinguished from the Quilty effect, which carries no clinical significance. Quilty lesions extend to the endocardial surface and include significant B-lymphocytes, distinguishing them from acute cellular rejection. AMR leads to intravascular macrophage accumulation with interstitial edema, hemorrhage, and neutrophilic infiltration in and around capillaries. The predominant feature of CAV is a diffuse, progressive thickening of the arterial intima that develops in the transplanted heart's epicardial and intramyocardial arteries.", "contents": "Heart Transplantation Rejection -- Histopathology. ACR is a mononuclear inflammatory response infiltrating myocardial tissue with predominant lymphocytic cells.\u00a0Immunohistologic assessment can confirm the presence of\u00a0CD-4 and CD-8 positive T lymphocytes with high affinity to interleukin-2 receptors. Increased intercellular adhesion molecules with high MHC-II expression on cardiac myocytes are present. These findings should be distinguished from the Quilty effect, which carries no clinical significance. Quilty lesions extend to the endocardial surface and include significant B-lymphocytes, distinguishing them from acute cellular rejection. AMR leads to intravascular macrophage accumulation with interstitial edema, hemorrhage, and neutrophilic infiltration in and around capillaries. The predominant feature of CAV is a diffuse, progressive thickening of the arterial intima that develops in the transplanted heart's epicardial and intramyocardial arteries."}
{"id": "article-22666_12", "title": "Heart Transplantation Rejection -- Histopathology -- Histological Grading", "content": "ISHLT ACR grading Grade 0\u00a0\u2013\u00a0No rejection Grade 1 R, mild\u00a0\u2013\u00a0Interstitial\u00a0and/or\u00a0perivascular infiltrate with up to one focus of myocyte damage. (grade 1A, 1B, and 2 in the 1990 system) Grade 2 R, moderate\u00a0\u2013\u00a0Two or more foci of infiltrates with associated myocyte damage. (grade 3A in 1990 system). Grade 3 R, severe\u2014Diffuse infiltrate with multifocal myocyte damage, with or without edema, hemorrhage, or vasculitis (grade 3B and 4 in the 1990 system). Immunopathologic findings for acute AMR include positive immunofluorescent staining for C4d, C3d, and Anti HLA-DR or immunoperoxidase staining for C4d and CD68 (or C3d). AMR grading Grade 0- Negative histologic and immunopathologic findings Grade 1- Presence of positive histologic and immunopathologic findings Grade 2- Presence of both histologic and immunopathologic findings Grade 3- Presence of severe histologic plus immunopathologic findings", "contents": "Heart Transplantation Rejection -- Histopathology -- Histological Grading. ISHLT ACR grading Grade 0\u00a0\u2013\u00a0No rejection Grade 1 R, mild\u00a0\u2013\u00a0Interstitial\u00a0and/or\u00a0perivascular infiltrate with up to one focus of myocyte damage. (grade 1A, 1B, and 2 in the 1990 system) Grade 2 R, moderate\u00a0\u2013\u00a0Two or more foci of infiltrates with associated myocyte damage. (grade 3A in 1990 system). Grade 3 R, severe\u2014Diffuse infiltrate with multifocal myocyte damage, with or without edema, hemorrhage, or vasculitis (grade 3B and 4 in the 1990 system). Immunopathologic findings for acute AMR include positive immunofluorescent staining for C4d, C3d, and Anti HLA-DR or immunoperoxidase staining for C4d and CD68 (or C3d). AMR grading Grade 0- Negative histologic and immunopathologic findings Grade 1- Presence of positive histologic and immunopathologic findings Grade 2- Presence of both histologic and immunopathologic findings Grade 3- Presence of severe histologic plus immunopathologic findings"}
{"id": "article-22666_13", "title": "Heart Transplantation Rejection -- History and Physical", "content": "All patients with a history of HTx should have a thorough history and physical exam performed. Medication history and immunosuppressant therapy compliance are requisites for the patient intake process. The development of new ventricular dysfunction, systolic, diastolic, or mixed, should raise suspicion for transplant rejection. The timing of rejection can act as a\u00a0clue to the diagnosis. Patients commonly present with orthopnea, shortness of breath,\u00a0 paroxysmal nocturnal dyspnea, syncope, palpitations, nausea/loss of appetite, weight gain, edema, arrhythmias (atrial flutter), oliguria, and hypotension. The physical exam can reveal signs of heart failure, such as elevated jugular venous pressure, extra sounds on auscultation, and peripheral edema.", "contents": "Heart Transplantation Rejection -- History and Physical. All patients with a history of HTx should have a thorough history and physical exam performed. Medication history and immunosuppressant therapy compliance are requisites for the patient intake process. The development of new ventricular dysfunction, systolic, diastolic, or mixed, should raise suspicion for transplant rejection. The timing of rejection can act as a\u00a0clue to the diagnosis. Patients commonly present with orthopnea, shortness of breath,\u00a0 paroxysmal nocturnal dyspnea, syncope, palpitations, nausea/loss of appetite, weight gain, edema, arrhythmias (atrial flutter), oliguria, and hypotension. The physical exam can reveal signs of heart failure, such as elevated jugular venous pressure, extra sounds on auscultation, and peripheral edema."}
{"id": "article-22666_14", "title": "Heart Transplantation Rejection -- Evaluation", "content": "The presence of the above symptoms and signs should raise alarms for HTR. HTR commonly gets diagnosed during surveillance endomyocardial biopsies. Typically, biopsies are performed every week for the first\u00a04 weeks, followed by every two weeks for the next\u00a06 weeks, followed by monthly biopsies for 3 to 4 months, and then every 3 months until the end of the first year. Routine myocardial biopsies after the first year have not shown superior benefits. [13] Chi NH et al recommended event principle biopsies at the end of 3 years due to the low rejection rate. [14] Diagnosis should be made based on the presence of the above-mentioned histologic findings. Biopsy-negative rejection is present in up to 20% of cases warranting the use of noninvasive monitoring; this includes measurement of troponin, Doppler echocardiography, cardiac magnetic resonance imaging (MRI), imaging using radiolabeled lymphocytes, antimyocin antibodies or annexin-V. [15] [16] [17] . T2 weighted cardiac MRI has shown promise in detecting early myocardial edema. [18] Gene expression profiling has emerged as an alternative to endomyocardial biopsy. E-IMAGE study showed non-inferior and safe results with gene expression profiling compared to endomyocardial biopsy. [19] AMR histologic findings usually accompany serum antibodies directed against HLA class I and II allograft antigens. The presence of histologic evidence of AMR, if present, is diagnostic. In the absence of HLA antibodies, non-HLA antibodies such as anti-endothelial, anti-vimentin, and anti-MCA/MICB also merit investigation.", "contents": "Heart Transplantation Rejection -- Evaluation. The presence of the above symptoms and signs should raise alarms for HTR. HTR commonly gets diagnosed during surveillance endomyocardial biopsies. Typically, biopsies are performed every week for the first\u00a04 weeks, followed by every two weeks for the next\u00a06 weeks, followed by monthly biopsies for 3 to 4 months, and then every 3 months until the end of the first year. Routine myocardial biopsies after the first year have not shown superior benefits. [13] Chi NH et al recommended event principle biopsies at the end of 3 years due to the low rejection rate. [14] Diagnosis should be made based on the presence of the above-mentioned histologic findings. Biopsy-negative rejection is present in up to 20% of cases warranting the use of noninvasive monitoring; this includes measurement of troponin, Doppler echocardiography, cardiac magnetic resonance imaging (MRI), imaging using radiolabeled lymphocytes, antimyocin antibodies or annexin-V. [15] [16] [17] . T2 weighted cardiac MRI has shown promise in detecting early myocardial edema. [18] Gene expression profiling has emerged as an alternative to endomyocardial biopsy. E-IMAGE study showed non-inferior and safe results with gene expression profiling compared to endomyocardial biopsy. [19] AMR histologic findings usually accompany serum antibodies directed against HLA class I and II allograft antigens. The presence of histologic evidence of AMR, if present, is diagnostic. In the absence of HLA antibodies, non-HLA antibodies such as anti-endothelial, anti-vimentin, and anti-MCA/MICB also merit investigation."}
{"id": "article-22666_15", "title": "Heart Transplantation Rejection -- Evaluation", "content": "During the first\u00a05 years, in patients with normal kidney functions, surveillance for CAV is performed with annual coronary angiography. Annual dobutamine stress echocardiography for patients with significant kidney disease is necessary. After\u00a05 years, annual dobutamine stress echocardiography with or without coronary angiography should be done based on the risk status of the recipient. Intravascular ultrasound should be performed when angiographic evidence is insufficient. Compared to coronary angiography, coronary CT angiography has offered a safer and equally accurate diagnostic approach for CAV. [20]", "contents": "Heart Transplantation Rejection -- Evaluation. During the first\u00a05 years, in patients with normal kidney functions, surveillance for CAV is performed with annual coronary angiography. Annual dobutamine stress echocardiography for patients with significant kidney disease is necessary. After\u00a05 years, annual dobutamine stress echocardiography with or without coronary angiography should be done based on the risk status of the recipient. Intravascular ultrasound should be performed when angiographic evidence is insufficient. Compared to coronary angiography, coronary CT angiography has offered a safer and equally accurate diagnostic approach for CAV. [20]"}
{"id": "article-22666_16", "title": "Heart Transplantation Rejection -- Treatment / Management", "content": "Treatment with immunosuppressant therapy post-transplant has significantly reduced rates of rejection. Immunosuppressive therapy usually consists of steroids, antiproliferative therapy such as cyclosporine, sirolimus/tacrolimus, and antimetabolites like azathioprine, mycophenolate mofetil, and rapamycin. The thirty-fourth heart transplant consensus from the ISHLT registry reported a lower rejection rate when treated with tacrolimus-based immunosuppression compared to recipients receiving cyclosporine. Treatment strategy depends on the type of\u00a0rejection.", "contents": "Heart Transplantation Rejection -- Treatment / Management. Treatment with immunosuppressant therapy post-transplant has significantly reduced rates of rejection. Immunosuppressive therapy usually consists of steroids, antiproliferative therapy such as cyclosporine, sirolimus/tacrolimus, and antimetabolites like azathioprine, mycophenolate mofetil, and rapamycin. The thirty-fourth heart transplant consensus from the ISHLT registry reported a lower rejection rate when treated with tacrolimus-based immunosuppression compared to recipients receiving cyclosporine. Treatment strategy depends on the type of\u00a0rejection."}
{"id": "article-22666_17", "title": "Heart Transplantation Rejection -- Treatment / Management", "content": "PGD is treated with high-dose inotropes to improve ventricular function. Patients failing medical therapy benefit from mechanical circulatory support such as an intra-aortic balloon pump, extracorporeal membrane oxygenator (ECMO), or temporary ventricular assist device. Hyperacute rejection is treatable with plasmapheresis, along with corticosteroids and intravenous immunoglobulin.", "contents": "Heart Transplantation Rejection -- Treatment / Management. PGD is treated with high-dose inotropes to improve ventricular function. Patients failing medical therapy benefit from mechanical circulatory support such as an intra-aortic balloon pump, extracorporeal membrane oxygenator (ECMO), or temporary ventricular assist device. Hyperacute rejection is treatable with plasmapheresis, along with corticosteroids and intravenous immunoglobulin."}
{"id": "article-22666_18", "title": "Heart Transplantation Rejection -- Treatment / Management -- ACR", "content": "The treatment strategy usually involves oral or intravenous steroids, anti-thymocyte globulin, and murine monoclonal antibody OKT3. Steroids inhibit the production of interleukin-1, 2, and 6, TNF-alpha, and IFN-gamma. Anti-thymocyte globulin prepared from immunized rabbits or horses causes cell death by complement-mediated lysis. OKT3 is a murine monoclonal antibody that inhibits T-cell function by binding to CD-3 antigen. Selection amongst these options is dictated based on the hemodynamic status of the recipient and the histologic severity of rejection. Hemodynamic compromise is defined by the presence of 1 or more of the following: Reduction in cardiac output (<4.0L/min) or cardiac index (<2.0L/min per m2) A decrease in pulmonary artery saturation (<50%) Elevation in the pulmonary artery to capillary wedge pressure (PCWP) Histology-based treatment for ACR:", "contents": "Heart Transplantation Rejection -- Treatment / Management -- ACR. The treatment strategy usually involves oral or intravenous steroids, anti-thymocyte globulin, and murine monoclonal antibody OKT3. Steroids inhibit the production of interleukin-1, 2, and 6, TNF-alpha, and IFN-gamma. Anti-thymocyte globulin prepared from immunized rabbits or horses causes cell death by complement-mediated lysis. OKT3 is a murine monoclonal antibody that inhibits T-cell function by binding to CD-3 antigen. Selection amongst these options is dictated based on the hemodynamic status of the recipient and the histologic severity of rejection. Hemodynamic compromise is defined by the presence of 1 or more of the following: Reduction in cardiac output (<4.0L/min) or cardiac index (<2.0L/min per m2) A decrease in pulmonary artery saturation (<50%) Elevation in the pulmonary artery to capillary wedge pressure (PCWP) Histology-based treatment for ACR:"}
{"id": "article-22666_19", "title": "Heart Transplantation Rejection -- Treatment / Management -- ACR", "content": "1.) Recipients with Grade IR rejection (grade 1A,1B, and 2 in the 1990 system) do not require treatment unless hemodynamically compromised.[21] Low-dose steroids are helpful in such cases.[22] For patients with hemodynamic compromise, pulse-dose\u00a0steroids orally or intravenously have shown a significant response.", "contents": "Heart Transplantation Rejection -- Treatment / Management -- ACR. 1.) Recipients with Grade IR rejection (grade 1A,1B, and 2 in the 1990 system) do not require treatment unless hemodynamically compromised.[21] Low-dose steroids are helpful in such cases.[22] For patients with hemodynamic compromise, pulse-dose\u00a0steroids orally or intravenously have shown a significant response."}
{"id": "article-22666_20", "title": "Heart Transplantation Rejection -- Treatment / Management -- ACR", "content": "2.) Grade 2R rejection (grade 3A in the 1990 system) is treated the same way as grade IR rejection with hemodynamic compromise. An oral pulse steroid (3-5mg/kg for 3-5 days) or 500-1000mg/day of IV methylprednisolone can be used. [21] Repeat biopsies are obtained weekly for 2 weeks to verify resolution. A repeat pulse dose steroid can be attempted in the event of persistent rejection.", "contents": "Heart Transplantation Rejection -- Treatment / Management -- ACR. 2.) Grade 2R rejection (grade 3A in the 1990 system) is treated the same way as grade IR rejection with hemodynamic compromise. An oral pulse steroid (3-5mg/kg for 3-5 days) or 500-1000mg/day of IV methylprednisolone can be used. [21] Repeat biopsies are obtained weekly for 2 weeks to verify resolution. A repeat pulse dose steroid can be attempted in the event of persistent rejection."}
{"id": "article-22666_21", "title": "Heart Transplantation Rejection -- Treatment / Management -- ACR", "content": "3.) Grade 2R rejection with hemodynamic compromise, grade 3R rejection, and steroid-resistant rejection episodes are treated with either anti-thymocyte globulin or OKT3 antibodies. The usual dose of OKT3 is 5mg/day intravenously for 10 to 14 days. Cyclosporine and mycophenolate are continued at pretreatment doses if therapeutic levels have been achieved. Other options include switching immunosuppressive therapy from cyclosporine to tacrolimus. Recipients treated with OKT3 antibodies should have levels of CD3-positive cells checked before and\u00a03 to\u00a05 days after the initiation of therapy. Antibiotic, antifungal, and antiviral prophylaxis are conventional adjunct therapies for patients treated with high-dose steroids or anti-lymphocyte therapy.", "contents": "Heart Transplantation Rejection -- Treatment / Management -- ACR. 3.) Grade 2R rejection with hemodynamic compromise, grade 3R rejection, and steroid-resistant rejection episodes are treated with either anti-thymocyte globulin or OKT3 antibodies. The usual dose of OKT3 is 5mg/day intravenously for 10 to 14 days. Cyclosporine and mycophenolate are continued at pretreatment doses if therapeutic levels have been achieved. Other options include switching immunosuppressive therapy from cyclosporine to tacrolimus. Recipients treated with OKT3 antibodies should have levels of CD3-positive cells checked before and\u00a03 to\u00a05 days after the initiation of therapy. Antibiotic, antifungal, and antiviral prophylaxis are conventional adjunct therapies for patients treated with high-dose steroids or anti-lymphocyte therapy."}
{"id": "article-22666_22", "title": "Heart Transplantation Rejection -- Treatment / Management -- AMR", "content": "AMR is hemodynamically more severe compared to ACR and has an association with a worse prognosis. Improved outcomes with Plasmapheresis in combination with corticosteroids and anti-thymocyte globulin or OKT3 antibody have undergone study. Treatment with CD20 monoclonal antibody Rituximab has shown some\u00a0promise.", "contents": "Heart Transplantation Rejection -- Treatment / Management -- AMR. AMR is hemodynamically more severe compared to ACR and has an association with a worse prognosis. Improved outcomes with Plasmapheresis in combination with corticosteroids and anti-thymocyte globulin or OKT3 antibody have undergone study. Treatment with CD20 monoclonal antibody Rituximab has shown some\u00a0promise."}
{"id": "article-22666_23", "title": "Heart Transplantation Rejection -- Treatment / Management -- AMR", "content": "Recurrent or resistant rejection despite 2 to 3 courses of OKT3 or anti-thymocyte globulin requires alternative approaches. These include photopheresis, total lymphoid irradiation, and immunosuppressive regimen changes.", "contents": "Heart Transplantation Rejection -- Treatment / Management -- AMR. Recurrent or resistant rejection despite 2 to 3 courses of OKT3 or anti-thymocyte globulin requires alternative approaches. These include photopheresis, total lymphoid irradiation, and immunosuppressive regimen changes."}
{"id": "article-22666_24", "title": "Heart Transplantation Rejection -- Differential Diagnosis", "content": "The differential diagnoses for heart transplantation rejection include the following: Primary graft dysfunction Secondary graft dysfunction Acute allograft rejection Cardiac allograft vasculopathy Amyloidosis Sarcoidosis Giant cell myocarditis Hereditary hemochromatosis Lymphoproliferative disorders such as non-Hodgkin lymphoma", "contents": "Heart Transplantation Rejection -- Differential Diagnosis. The differential diagnoses for heart transplantation rejection include the following: Primary graft dysfunction Secondary graft dysfunction Acute allograft rejection Cardiac allograft vasculopathy Amyloidosis Sarcoidosis Giant cell myocarditis Hereditary hemochromatosis Lymphoproliferative disorders such as non-Hodgkin lymphoma"}
{"id": "article-22666_25", "title": "Heart Transplantation Rejection -- Prognosis", "content": "The one-year survival rate post-HTx is close to 90%. Median survival for patients receiving HTx has improved significantly. Patients requiring extracorporeal membrane oxygenation support before\u00a0HTx have a worse prognosis. Acute allograft rejection is responsible for 10% of deaths within the first\u00a03 years. The incidence of CAV increases steadily\u00a0after transplantation. Malignancy is the most common cause of mortality beginning at 5 years post-HTx. About 2-4% of heart transplant recipients end up receiving repeat retransplantation. Overall outcomes after retransplantation are inferior compared to primary HTx.", "contents": "Heart Transplantation Rejection -- Prognosis. The one-year survival rate post-HTx is close to 90%. Median survival for patients receiving HTx has improved significantly. Patients requiring extracorporeal membrane oxygenation support before\u00a0HTx have a worse prognosis. Acute allograft rejection is responsible for 10% of deaths within the first\u00a03 years. The incidence of CAV increases steadily\u00a0after transplantation. Malignancy is the most common cause of mortality beginning at 5 years post-HTx. About 2-4% of heart transplant recipients end up receiving repeat retransplantation. Overall outcomes after retransplantation are inferior compared to primary HTx."}
{"id": "article-22666_26", "title": "Heart Transplantation Rejection -- Complications", "content": "The complications that can manifest with heart transplantation rejection are as follows: Repeated endomyocardial biopsy can cause tricuspid valve regurgitation. [22] Graft failure Atrial arrhythmia Lymphoproliferative malignancy Cardiac allograft vasculopathy Acute graft rejection Increased risk of secondary infections. Serum sickness due to anti-thymocyte globulin Acute myocardial infarction Repeat heart transplantation Death", "contents": "Heart Transplantation Rejection -- Complications. The complications that can manifest with heart transplantation rejection are as follows: Repeated endomyocardial biopsy can cause tricuspid valve regurgitation. [22] Graft failure Atrial arrhythmia Lymphoproliferative malignancy Cardiac allograft vasculopathy Acute graft rejection Increased risk of secondary infections. Serum sickness due to anti-thymocyte globulin Acute myocardial infarction Repeat heart transplantation Death"}
{"id": "article-22666_27", "title": "Heart Transplantation Rejection -- Deterrence and Patient Education", "content": "It is important to stress the importance of regular follow-up and medication compliance after a recent heart transplant. Patients should receive education about the risks and benefits of immunosuppressive therapy, including the potential for rejection despite using immunosuppressive therapy. Teaching patients\u00a0about early symptoms and signs of rejection can help prevent dangerous consequences. Knowledge about the increased risk of atrial arrhythmia and lymphoproliferative disorder due to immunosuppressive therapy should be provided to all heart transplant patients.", "contents": "Heart Transplantation Rejection -- Deterrence and Patient Education. It is important to stress the importance of regular follow-up and medication compliance after a recent heart transplant. Patients should receive education about the risks and benefits of immunosuppressive therapy, including the potential for rejection despite using immunosuppressive therapy. Teaching patients\u00a0about early symptoms and signs of rejection can help prevent dangerous consequences. Knowledge about the increased risk of atrial arrhythmia and lymphoproliferative disorder due to immunosuppressive therapy should be provided to all heart transplant patients."}
{"id": "article-22666_28", "title": "Heart Transplantation Rejection -- Enhancing Healthcare Team Outcomes", "content": "Heart transplantation and post-transplant care are demanding and critical. It requires an interprofessional approach involving the patient, a heart transplant cardiologist, a heart transplant surgeon, a social worker, nursing staff, pharmacists, physical therapists, dietary assistants, and financial educators. The ISHLT guidelines recommend an interprofessional approach at all HTx centers. The use of an interprofessional approach has demonstrated improved chronic illness management. [23] Implementation of daily interprofessional rounds has shown improvement in recovery time post-HTx. [24] Interprofessional physician and nursing staff involvement after a heart transplant\u00a0is equally important. Increasing patient education and explaining the importance of surveillance biopsy and medical compliance can improve overall outcomes in HTx patients.", "contents": "Heart Transplantation Rejection -- Enhancing Healthcare Team Outcomes. Heart transplantation and post-transplant care are demanding and critical. It requires an interprofessional approach involving the patient, a heart transplant cardiologist, a heart transplant surgeon, a social worker, nursing staff, pharmacists, physical therapists, dietary assistants, and financial educators. The ISHLT guidelines recommend an interprofessional approach at all HTx centers. The use of an interprofessional approach has demonstrated improved chronic illness management. [23] Implementation of daily interprofessional rounds has shown improvement in recovery time post-HTx. [24] Interprofessional physician and nursing staff involvement after a heart transplant\u00a0is equally important. Increasing patient education and explaining the importance of surveillance biopsy and medical compliance can improve overall outcomes in HTx patients."}
{"id": "article-22666_29", "title": "Heart Transplantation Rejection -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Heart Transplantation Rejection -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}